RhumbLine Advisers’s Asterias Biotherapeutics Inc. Series A AST Stock Holding History

RhumbLine Advisers’s Portfolio AST Stock Details AST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-23,093	Closed	-$33K	–	3006
2018 Q1	$33K	Hold	23,093	–	–	﹤0.01%	2807
2017 Q4	$52K	Hold	23,093	–	–	﹤0.01%	2814
2017 Q3	$79K	Buy	23,093 +795	+4%	+$2.67K	﹤0.01%	2874
2017 Q2	$79K	Buy	22,298 +7,390	+50%	+$24.3K	﹤0.01%	2907
2017 Q1	$51K	Buy	14,908 +858	+6%	+$3.34K	﹤0.01%	2824
2016 Q4	$65K	Buy	14,050 +1,786	+15%	+$7.37K	﹤0.01%	2817
2016 Q3	$52K	Buy	12,264 +600	+5%	+$1.94K	﹤0.01%	2851
2016 Q2	$28K	Buy	+11,664	New	+$42.2K	﹤0.01%	2971
2015 Q4	–	Sell	-11,199	Closed	-$43K	–	3076
2015 Q3	$43K	Buy	+11,199	New	+$51.4K	﹤0.01%	2996

Other funds holding AST

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

RhumbLine Advisers's AST Position: Q2 2018 in Review

RhumbLine Advisers sold out of Asterias Biotherapeutics Inc. Series A (AST) in Q2 2018, closing a stake of 23,093 shares — an estimated $33K sold.

RhumbLine Advisers first reported a position in AST in Q3 2015 and held it in 9 quarters. The position peaked at $79K in Q3 2017. 62 funds tracked by Wall St. Rank hold AST as of Q2 2018.

RhumbLine Advisers reported no remaining Asterias Biotherapeutics Inc. Series A position as of Q2 2018 after selling out during the quarter.
RhumbLine Advisers sold 23,093 Asterias Biotherapeutics Inc. Series A shares in Q2 2018, an estimated $33K.
RhumbLine Advisers first reported a position in Asterias Biotherapeutics Inc. Series A in Q3 2015 and held it in 9 quarters.
RhumbLine Advisers's Asterias Biotherapeutics Inc. Series A position peaked at $79K in Q3 2017.
62 funds tracked by Wall St. Rank held Asterias Biotherapeutics Inc. Series A as of Q2 2018.

Based on RhumbLine Advisers's 13F filing for Q2 2018, filed 6 Aug 2018.